Tocilizumab

CHEMBL1237022 Phase 4 ได้รับการอนุมัติ Antibody
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

This biologic medication blocks the action of interleukin-6 (IL-6), an immune protein that drives inflammation, and is used to treat rheumatoid arthritis, certain forms of juvenile arthritis, giant cell arteritis, and severe cytokine release syndrome (including that caused by COVID-19 or CAR-T cell therapy). It is given either as an intravenous infusion or a subcutaneous injection. Patients need regular monitoring for infections, liver function, and blood counts.

ด้านการรักษา

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

This biologic medication blocks the action of interleukin-6 (IL-6), an immune protein that drives inflammation, and is used to treat rheumatoid arthritis, certain forms of juvenile arthritis, giant cell arteritis, and severe cytokine release syndrome (including that caused by COVID-19 or CAR-T cell therapy). It is given either as an intravenous infusion or a subcutaneous injection. Patients need regular monitoring for infections, liver function, and blood counts.

Yes, Tocilizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1237022. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.